Case studies highlight peril to treatment advances across several disease states
August 14, 2024 (WASHINGTON, DC) The Partnership to Fight Chronic Disease (PFCD) today announced the release of a new data set that highlights critical risks posed to the development and delivery of new treatments and cures for patients living with lung and rare cancers, autoimmune and mental health conditions, stroke, cardiovascular disease and diabetes. The analysis, conducted by Lumanity, explores the treatment advances that likely would have been lost had the Medicare Drug Price Negotiation Program of the Inflation Reduction Act (IRA) been in place 10 years ago. By using real life examples of innovation losses, the extent of the unintended consequences of the IRA to some of our country’s most vulnerable patients is evident.
Full press release HERE.
FACT SHEETS:
